Flucelvax
Flucelvax has been studied in 1 paper since 2025: 1 trial in people. The newest paper, Oct 30, 2025: “Comparative analysis of cellular immune responses to four seasonal inactivated influenza vaccines in younger and older adults”.
1 paper studies it2 findingsUpdated
“In younger participants, FCEL induced a higher frequency of H1 AIM+ T cells at day 7 (P = 0.007) compared to FSD, and these levels were maintained up to 28 d post-vaccination (P = 0.04).”
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Centers for Disease Control and Prevention and others
- Human trial1
Studies in people
1 study gave flucelvax to people and measured what changed.
Trial52 peopleThe majority of individuals were female (older adults: ∼65% female, younger adults: ∼85% female), with FCEL having the highest overall percentage at 92%aged 25 to 8590 d
Journal of immunology (Baltimore, Md. : 1950), Oct 30, 2025
What did studies of Flucelvax find?
2Studies of Flucelvax measured 2 outcomes; the most studied are immune response (1 study) and immune response (1).
Immune response
upin humans1
1 study
Immune response
upin humans1
Flucelvax improves immune response in younger participants, compared to FSD.
“In younger participants, FCEL induced a higher frequency of H1 AIM+ T cells at day 7 (P = 0.007) compared to FSD, and these levels were maintained up to 28 d post-vaccination (P = 0.04).”
Human trialin younger participants, compared to FSD90 d
Journal of immunology (Baltimore, Md. : 1950)
Immune response
upin humans1
1 study
Immune response
upin humans1
Flucelvax improves immune response in humans.
“FCEL, produced in mammalian cells, was more effective than the egg-produced FSD in younger adults.”
Human trial
Journal of immunology (Baltimore, Md. : 1950)